Effective weight-loss treatments will unquestionably increase short-term pharmacy plan spending, with the potential to reduce longer-term medical plan costs by avoiding some of the harmful complications of diseases that are driven, in part, by obesity
This way, your progress feels visible rather than overwhelming, which is important when you're weeks away from your full dose and wondering if any of this is actually working
A few key takeaways Some important things to consider in light of this letter that has import into compounding and drug production in general: This letter documents systemic failure, not isolated incidents
One case report has been received of adverse reactions with phentermine and fluoxetine
The index currently sits slightly above the SODay moving average, a key technical support level
The upfront costs of GLP-1s are an ongoing concern for both public and private payers, and some employers and state Medicaid programs are now restricting coverage, despite recognizing their effectiveness at treating obesity